Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated.
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
Ghiorzo, Paola;Pastorino, Lorenza;
2018-01-01
Abstract
Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
helgadottir jmedgenet-2018-105610.1.full.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
231.11 kB
Formato
Adobe PDF
|
231.11 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
